MLICM
IOVA icon

Metropolitan Life Insurance Company (MetLife)’s Iovance Biotherapeutics IOVA Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12,474
Closed -$185K – 1049
2024
Q1 		$185K Sell
12,474
-892
-7% -$10.4K 0.01% 749
2023
Q4 		$109K Hold
13,366
– – 0.01% 1031
2023
Q3 		$60.8K Buy
13,366
+1,997
+18% +$13K ﹤0.01% 1293
2023
Q2 		$80K Buy
+11,369
New +$81.4K ﹤0.01% 1140
2023
Q1 		– Sell
-9,119
Closed -$58.3K – 2386
2022
Q4 		$58.3K Hold
9,119
– – ﹤0.01% 1374
2022
Q3 		$87.4K Hold
9,119
– – ﹤0.01% 1092
2022
Q2 		$101K Buy
+9,119
New +$120K ﹤0.01% 1048
2022
Q1 		– Sell
-5,082
Closed -$97K – 2458
2021
Q4 		$97K Buy
5,082
+42
+0.8% +$925 ﹤0.01% 2505
2021
Q3 		$124K Buy
+5,040
New +$119K ﹤0.01% 2399
2021
Q2 		– Sell
-10,013
Closed -$317K – 2786
2021
Q1 		$317K Sell
10,013
-451
-4% -$18.7K ﹤0.01% 1716
2020
Q4 		$486K Sell
10,464
-204
-2% -$8.1K 0.01% 1367
2020
Q3 		$351K Sell
10,668
-77
-0.7% -$2.36K 0.01% 1443
2020
Q2 		$295K Sell
10,745
-24,719
-70% -$813K 0.01% 1555
2020
Q1 		$1.06M Sell
35,464
-1,094
-3% -$29K 0.02% 650
2019
Q4 		$1.01M Sell
36,558
-682
-2% -$15.5K 0.02% 897
2019
Q3 		$678K Buy
37,240
+1,855
+5% +$41K 0.01% 1101
2019
Q2 		$868K Hold
35,385
– – 0.01% 976
2019
Q1 		$337K Hold
35,385
– – 0.01% 1555
2018
Q4 		$313K Buy
35,385
+8,010
+29% +$77.3K 0.01% 1526
2018
Q3 		$308K Buy
+27,375
New +$389K 0.01% 1698
2017
Q2 		– Sell
-37,345
Closed -$278K – 2576
2017
Q1 		$278K Hold
37,345
– – ﹤0.01% 2059
2016
Q4 		$260K Hold
37,345
– – ﹤0.01% 2176
2016
Q3 		$307K Buy
37,345
+1,248
+3% +$10.6K ﹤0.01% 2050
2016
Q2 		$292K Hold
36,097
– – ﹤0.01% 2066
2016
Q1 		$183K Hold
36,097
– – ﹤0.01% 2227
2015
Q4 		$279K Buy
36,097
+4,242
+13% +$29.4K ﹤0.01% 2019
2015
Q3 		$183K Sell
31,855
-7,128
-18% -$55.5K ﹤0.01% 2346
2015
Q2 		$357K Buy
+38,983
New +$435K ﹤0.01% 1986

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s IOVA Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Iovance Biotherapeutics (IOVA) in Q2 2024, closing a stake of 12,474 shares — an estimated $185K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in IOVA in Q2 2015 and held it in 28 quarters. The position peaked at $1.06M in Q1 2020. 295 funds tracked by Wall St. Rank hold IOVA as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Iovance Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 12,474 Iovance Biotherapeutics shares in Q2 2024, an estimated $185K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Iovance Biotherapeutics in Q2 2015 and held it in 28 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Iovance Biotherapeutics position peaked at $1.06M in Q1 2020.
  • 295 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.